Odense
Odense
Odense, Denmark344 results · Page 1 of 14
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TEENS Multi-site Trial | Self-Injurious Behavior | Active, not recruiting | Not applicable | 2026-10-09 | NCT05179655 | |
| LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 2 | 2026-10-08 | NCT07186101 | |
| Enlighten Study: The EV-ICD Post Approval Registry | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tachycardia, cardiovascular disorder, heart disorder | Active, not recruiting | Not stated | 2026-10-08 | NCT06048731 | |
| Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Body Weight, Crohn disease, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-07 | NCT06937099 | |
| Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Body Weight, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, nutritional disorder, obesity disorder, overnutrition, ulcerative colitis | Recruiting | Phase 3 | 2026-10-07 | NCT06937086 | |
| Progressive Resistance Training for Adults With External Snapping Hip | Coxa Saltans External; External Snapping Hip | Recruiting | Not applicable | 2026-10-07 | NCT06924164 | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-07 | NCT05243797 | |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-07 | NCT04910685 | |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04663347 | |
| Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Richter transformation, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04623541 | |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT03625037 | |
| DAN-RELEASE - Reconsidering Long-Term Aspirin in the Elderly Patients With Stable Ischemic Heart Disease | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2026-10-05 | NCT07795398 | |
| SCARFREE-001: Verteporfin for Scar Prevention | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, severe cutaneous adverse reaction | Not yet recruiting | Phase 2 | 2026-10-05 | NCT07488988 | |
| The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial | Bacterial Infections and Mycoses, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, bacterial infectious disease, bacterial infectious disease with sepsis, cardiovascular disorder, heart disorder, heart valve disorder | Recruiting | Not applicable | 2026-10-05 | NCT07442357 | |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07210723 | |
| The Intensive Care Platform Trial | Critical Illness, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 4 | 2026-10-05 | NCT06667999 | |
| The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | Bone Diseases, Metabolic, Nutritional and Metabolic Diseases, Osteopenia, bone disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, musculoskeletal system disorder, type 2 diabetes mellitus | Active, not recruiting | Phase 2 | 2026-10-05 | NCT06050577 | |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-10-05 | NCT05902169 | |
| Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL | chronic lymphocytic leukemia/small lymphocytic lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT05791409 | |
| A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy (DCM) | Recruiting | Phase 3 | 2026-10-02 | NCT07771465 | |
| Optical Coherence Tomography in Acute Vessel Evaluation | acute coronary syndrome, cardiovascular disorder, heart disorder, myocardial ischemia, vascular disorder | Enrolling by invitation | Not applicable | 2026-10-02 | NCT07422688 | |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 3 | 2026-10-02 | NCT06617325 | |
| Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations | Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, immune system disorder, interstitial lung disease, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, pulmonary sarcoidosis, respiratory system disorder, sarcoidosis | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT05890729 | |
| (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Active, not recruiting | Phase 2 | 2026-10-02 | NCT03731260 | |
| Vascular Complications After Kidney Transplantation | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hypertension, Renovascular, Male Urogenital Diseases, Urogenital Diseases, cardiovascular disorder, heart disorder, heart failure, hypertensive disorder, kidney disorder, renal hypertension, urinary system disorder, vascular disorder | Recruiting | Not stated | 2026-10-01 | NCT07531966 |